Log in

Relevant bibliographies by topics / ALK positive Lung Cancer / Dissertations / Theses

To see the other types of publications on this topic, follow the link: ALK positive Lung Cancer.

Dissertations / Theses on the topic 'ALK positive Lung Cancer'

Author: Grafiati

Published: 2 June 2025

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 20 dissertations / theses for your research on the topic 'ALK positive Lung Cancer.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse dissertations / theses on a wide variety of disciplines and organise your bibliography correctly.

1

Takahashi, Tsuyoshi. "Clinicopathologic Features of Non-Small Cell Lung Cancer with EML4-ALK Fusion Gene." Kyoto University, 2010. http://hdl.handle.net/2433/120559.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Itchins, Malinda. "Investigating Resistance To Tyrosine Kinase Inhibitor Therapy In Alk Gene Rearranged Non-Small Cell Lung Cancer- From Bedside To Bench And Back." Thesis, University of Sydney, 2020. https://hdl.handle.net/2123/23392.

Full text

Abstract:

Since its discovery in 2007, ALK-rearranged non-small cell lung cancer (NSCLC) has emerged as a unique and highly heterogeneous rare subgroup of lung cancer, more often affecting the young, fit and pauci-smokers. With the introduction of ALK-inhibitor (ALKi) therapy, quality of life and survival has been revolutionised for those diagnosed with advanced disease. Newer generation ALKi therapies have further improved survival gains, whilst vitally protecting the brain, as ALK NSCLC has a predilection to metastasise to the brain. With several ALKi’s now in the clinic, and more in development, ho

APA, Harvard, Vancouver, ISO, and other styles

3

Recondo, Gonzalo. "Resistance Mechanisms to ALK Tyrosine Kinase Inhibitors (TKIs) in NSCLC." Thesis, Université Paris-Saclay (ComUE), 2019. http://www.theses.fr/2019SACLS248/document.

Full text

Abstract:

Les analyses moléculaires et la classification des adénocarcinomes bronchiques ont conduit au développement de thérapies ciblées sélectives visant à améliorer le contrôle de la maladie et la survie des patients. ALK (anaplastic lymphoma kinase) est un récepteur tyrosine kinase de la famille des récepteurs de l'insuline. Des réarrangements chromosomiques impliquant le domaine kinase d’ALK sont présents dans environ 3 à 6% des patients atteints d'un adénocarcinome bronchique. La protéine de fusion provoque une activation du domaine kinase de manière constitutive et indépendante du ligand. Lorlat

APA, Harvard, Vancouver, ISO, and other styles

4

Tsuji, Takahiro. "Alectinib Resistance in ALK-Rearranged Lung Cancer by Dual Salvage Signaling in a Clinically Paired Resistance Model." Kyoto University, 2019. http://hdl.handle.net/2433/242907.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Moti, Naushad. "ALK-positive anaplastic large cell lymphoma is propagated by cancer stem cells that potentially originate from an early haematopoietic progenitor." Thesis, University of Cambridge, 2012. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.610843.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Funazo, Tomoko. "Acquired Resistance to Alectinib in ALK-Rearranged Lung Cancer Due to ABCC11/MRP8 Overexpression in a Clinically Paired Resistance Model." Kyoto University, 2020. http://hdl.handle.net/2433/258997.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Hirsch, Jameson K., Andrea R. Floyd, and Paul R. Duberstein. "Perceived Health in Lung Cancer Patients: The Role of Positive and Negative Affect." Digital Commons @ East Tennessee State University, 2012. https://dc.etsu.edu/etsu-works/684.

Full text

Abstract:

Purpose: To examine the association of affective experience and health-related quality of life in lung cancer patients, we hypothesized that negative affect would be positively, and positive affect would be negatively, associated with perceived health. Methods: A sample of 133 English-speaking lung cancer patients (33% female; mean age = 63.68 years old, SD = 9.37) completed a battery of self-report surveys. Results: Results of our secondary analysis indicate that trait negative affect was significantly associated with poor physical and social functioning, greater role limitations due to emoti

APA, Harvard, Vancouver, ISO, and other styles

8

Mattsson, Johanna. "An integrative strategy for targeted evaluation of biomarker expression in non-small cell lung cancer." Doctoral thesis, Uppsala universitet, Molekylär och morfologisk patologi, 2016. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-285844.

Full text

Abstract:

Despite improvements in therapy, the prognosis for non-small cell lung cancer (NSCLC) patients remains poor, and cure is only possible in localized tumors after surgical resection. A new generation of targeted cancer drugs has led to the expectation that lung cancer therapy can be significantly improved, but these drugs are today only an option in a small subset of NSCLC patients, and their effect is temporary. Therefore, the aim of this thesis was to characterize NSCLC in order to find new treatment targets and to evaluate biomarkers that further optimize therapy selection. In Paper I, the ex

APA, Harvard, Vancouver, ISO, and other styles

9

Pinot, Roussel Hélène. "Étude du microenvironnement immunitaire des tumeurs du poumon avec réarrangement ALK et rôle des lymphocytes résidents mémoires dans les tumeurs muqueuses (poumon, ORL)." Thesis, Sorbonne Paris Cité, 2016. http://www.theses.fr/2016USPCB086.

Full text

Abstract:

Les cancers du poumon se placent au quatrième rang des cancers tous sexes confondus et constituent la première cause de mortalité par cancer pour l’homme et la troisième chez la femme. Le pronostic est sombre avec une survie relative globale estimée à 43% à 1 an et 14% à 5 ans. Les adénocarcinomes, les carcinomes épidermoïdes et les carcinomes à grandes cellules selon la classification OMS 2015 correspondent à 85% de ces cancers. Les adénocarcinomes pulmonaires ont été scindés en de multiples entités grâce aux progrès des techniques de biologie moléculaire ayant permis d’identifier différentes

APA, Harvard, Vancouver, ISO, and other styles

10

Pailler, Emma. "Identification de biomarqueurs de sensibilité et de résistance aux inhibiteurs de tyrosine kinase dans les cellules tumorales circulantes de patients atteints de cancers bronchiques non à petites cellules - Cas des remaniements ALK et ROS1." Thesis, Université Paris-Saclay (ComUE), 2016. http://www.theses.fr/2016SACLS410/document.

Full text

Abstract:

Les cellules tumorales circulantes (CTC) représentent un large champ de recherche susceptible de fournir des informations tant cliniques que fondamentales. Les CTC proviennent de tumeurs primitives ou métastatiques et représentent une population hétérogène de cellules très rares dans le flux sanguin. Leur caractérisation moléculaire est un défi technologique qui requiert des méthodes très sensibles et spécifiques. Dans les cancers bronchiques non à petites cellules (CBNPC), les CTC ont un véritable intérêt car les biopsies tumorales ne permettent pas toujours de réaliser les analyses moléculai

APA, Harvard, Vancouver, ISO, and other styles

11

Sorrentino, Domenico. "Rôle et régulation de l'autophagie dans les tumeurs exprimant l'oncogène ALK." Thesis, Toulouse 3, 2020. http://www.theses.fr/2020TOU30260.

Full text

Abstract:

Le lymphome anaplasique à grandes cellules ALK positif (LAGC ALK+) est un cancer pédiatrique très agressif. Il se caractérise par des translocations chromosomiques impliquant toujours le gène ALK et différents autres gènes, partenaires de translocation. NPM-ALK (Nucleophosmine- Anaplastic Lymphoma Kinase) est la protéine de fusion à activité tyrosine kinase la plus fréquemment observée. Elle résulte de la translocation chromosomique t(2;5)(p23 ;q35) et l'activation constitutive de son domaine catalytique permet le développement du lymphome, par l'activation de nombreuses voies de signalisation

APA, Harvard, Vancouver, ISO, and other styles

12

Piton, Nicolas. "Optimisation de la prise en charge diagnostique, pronostique et théranostique des carcinomes broncho-pulmonaires humains : des techniques d’imagerie in vivo à la biologie moléculaire. Ligation -dependent RT-PCR : a new specific and low-cost technique to detect ALK, ROS and RET rearrangements in lung adenocarcinoma A new assay for detection of theranostic gene translocations and MET exon 14 skipping in thoracic oncology. One-year perspective routine LD-RT-PCR in 413 newly diagnosed lung tumors STK11 mutations are associated with lower PDL1 expression in lung adenocarcinoma BRAF V600E mutation is not always present as expected ! A case report of lung and thyroid carcinomas A novel method for in vivo imaging of solitary lung nodules using navigational bronchoscopy and confocal laser microendoscopy." Thesis, Normandie, 2019. http://www.theses.fr/2019NORMR119.

Full text

Abstract:

Le carcinome pulmonaire est une affection grave et fréquente dont la prise en charge a été bouleversée ces dernières années, tant sur le plan diagnostique que pronostique ou « théranostique » avec l’avènement des « thérapies ciblées ». Ces dernières permettent une nette amélioration de la survie et du confort des patients éligibles, mais ne sont pas sans compliquer le travail médical, depuis le diagnostic de la maladie jusqu’au suivi régulier du patient, sans oublier le choix des traitements ou les problèmes techniques posés par la multiplication arborescente des altérations moléculaires à rec

APA, Harvard, Vancouver, ISO, and other styles

13

Liu, Chien-Ting, and 劉建廷. "Molecular Dynamic Simulation to Survey Possible Resistance Mechanisms of ALK Inhibitors to G1202R Mutation in EML4-ALK Translocation Positive Non-small Cell Lung Cancer." Thesis, 2018. http://ndltd.ncl.edu.tw/handle/cx98db.

Full text

Abstract:

碩士<br>國立中山大學<br>醫學科技研究所<br>106<br>Non-small cell lung cancers (NSCLC) with ALK rearrangements are highly sensitive to ALK tyrosine kinase inhibition (TKI). The multi-targeted TKI crizotinib, ceritinib, alectinib, and brigatinib have been approved by the U.S. food and drug administration (FDA) in 2011, 2014, 2015, and 2017 for treating patients with advanced ALK-positive NSCLC. However, most patients develop resistance within one to two years. The G1202R mutation has been reported to be resistant to the TKI above. The possible treatment strategies are still critically lacking. The purpose of t

APA, Harvard, Vancouver, ISO, and other styles

14

Lee, Szu-Hui, and 李思慧. "Novel Target in the Treatment of Non-small Cell Lung Cancer Anaplastic Lymphoma Kinase (ALK) Positive Rate of NSCLC in Taiwan." Thesis, 2015. http://ndltd.ncl.edu.tw/handle/jz37at.

Full text

Abstract:

碩士<br>國立臺灣大學<br>公共衛生碩士學位學程<br>103<br>Study Aims: Anaplastic lymphoma kinase (ALK) inhibitor, a new targeted agent, has become the standard treatment for non-small lung cancer (NSCLC) harboring ALK gene mutation. This study was designed to investigate the anaplastic lymphoma kinase (ALK) gene mutation rate of non-small lung cancer patients in Taiwan. This study could establish the prevalence rate of ALK mutation in Taiwan and help clinicians to evaluate the optimal timing of performing ALK mutational analysis in late stage NSCLC patients. Methods: We retrospectively collect the database from

APA, Harvard, Vancouver, ISO, and other styles

15

Liu, Kang-Yi, and 劉岡易. "Cost-Utility Analysis of Crizotinib as First Line Medication on Late Stage ALK Positive Non-Small Cell Lung Cancer Patients in Taiwan." Thesis, 2016. http://ndltd.ncl.edu.tw/handle/30820932153784582551.

Full text

Abstract:

碩士<br>國立臺灣大學<br>健康政策與管理研究所<br>104<br>Purpose: This study aimed to estimate the cost-utility of Crizotinib treatment as first-line medication on late stage ALK positive non-small-cell lung cancer patients compare to current chemotherapy from the payer’s perspective in Taiwan. Methods: A cost-utility analysis was conducted using a Markov model from the National Health Insurance Administrative perspective. Real-world data and costs were obtained from National Health Insurance Reasearch Database to calculate the progression-free survival and overall survival of late stage NSCLC patients using che

APA, Harvard, Vancouver, ISO, and other styles

16

Kuo, Wei-Ying, and 郭蔚瑩. "Aldehyde dehydrogenase 1 positive non-small cell lung carcinoma H1299 cells exhibits cancer stem cell characteristic." Thesis, 2011. http://ndltd.ncl.edu.tw/handle/43763667757025676947.

Full text

Abstract:

碩士<br>國立陽明大學<br>生物醫學影像暨放射科學系暨研究所<br>99<br>Tumors are organized in a heterogeneous manner with a subpopulation of limited number(less than 5%) called Cancer stem cells (CSCs) with the ability to self-renewal and giving rise to a differentiated progeny that represents most of the tumor populations. CSCs are chemoresistant and metastatic, two features that very likely contribute to the poor prognosis of advanced cancer. Furthermore, CSCs are also the key player in tumor recurrence. Therefore, exploring cell markers or function specific for CSCs identification is urgently needed. Recently, Leu

APA, Harvard, Vancouver, ISO, and other styles

17

Branco, Paula Andreia de Paiva Castelo. "Importância do Alectinib na terapêutica de doentes com metáteses cerebrais." Master's thesis, 2021. http://hdl.handle.net/10316/98522.

Full text

Abstract:

Trabalho Final do Mestrado Integrado em Medicina apresentado à Faculdade de Medicina<br>Introdução: O carcinoma pulmonar de não pequenas células (CPCNP) com rearranjo anaplastic lymphoma kinase (ALK) positivo em estádio avançado permite uma abordagem terapêutica dirigida, através dos novos inibidores tirosina cinase (TKI). Este subtipo molecular tem maior propensão para a metastização cerebral, por isso, requer inibidores com elevada eficácia no

APA, Harvard, Vancouver, ISO, and other styles

18

Wagner, Tabea. "FRET-Bildgebung zum Nachweis der Phopshorylierung der anaplastic lymhoma kinase (ALK) im nicht-kleinzelligen Bronchialkarzinom." Doctoral thesis, 2018. http://hdl.handle.net/11858/00-1735-0000-002E-E3F0-F.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

"The positive role of thromboxane A2 (TxA2) and Its receptor in lung cancer cell growth induced by smoking carcinogen 4-methylnitrosamino-1-3-pyridyl-1-butanone (NNK)." 2012. http://library.cuhk.edu.hk/record=b5549645.

Full text

Abstract:

肺癌是一個世界性的健康難題。大量研究證據顯示，煙草及其致癌物NNK對環氧酶（COX）-2及其下游產物具有促進效應。血栓素（TxA）2是COX-2的關鍵性下游產物之一，該論文闡述了TxA2在NNK導致的肺癌增長中的可能作用。<br>我們發現相对于非吸烟者，吸煙者肺癌組織表达更高水平的TxA2合酶（TxAS）。NNK可以刺激培養的肺癌細胞TxA2合成。用TxAS抑制劑和TxA2受體（TP）拮抗劑分別阻抑TxA2的合成與功能可以引起細胞凋亡，從而有效抑制NNK導致的細胞增殖效應。在TxA2合成受抑制的情況下，TP激動劑U46619幾乎可以重建NNK效應，說明TP在NNK效應中的重要作用。研究還顯示，激活的TP可以通過PI3K/Akt和ERK通路進一步激活CREB，從而參與NNK對肺癌細胞的促生長效應。<br>緊接著，我們的研究顯示TP 可以調節NNK對COX-2 和TxA2的誘導，而且發現NNK刺激的TxA2合成主要依賴於COX-2活性。COX-2和TxA2功能抑製劑對NNK的促細胞生長作用具有相似的抑制效用。考慮到TP是TxA2的功能受體，該資料說明TP在NNK處理的肺癌細胞中傳遞了上游因子COX-2的促腫瘤作用。在使用COX-2小干擾RNA（siRNA）抑制NNK作用的情況下，TP激動劑U46619幾乎可以恢復NNK的效應證實了TP的傳遞者角色。研究還發現 TPα而不是TPβ在培養的

APA, Harvard, Vancouver, ISO, and other styles

20

Chen, Hsing-Yen, and 陳杏燕. "Enhancing efficacy of therapeutic EGFR DNA vaccine by depletion of CD25+ regulatory T cell in a mouse model of metastatic EGFR positive lung cancer." Thesis, 2012. http://ndltd.ncl.edu.tw/handle/37931461382047177787.

Full text

Abstract:

碩士<br>國立中興大學<br>生命科學院碩士在職專班<br>100<br>Previously, we reported that gene gun administration with naked DNA plasmids coding for the extracellular domains of the xenogenic EGFR gene can induce strong CTL activity and control endogenous EGFR -expressing LL2 lung tumors growth in subcutaneous tumor models in mice. However, our present study observed that gene gun administration EGFR DNA vaccines alone lack of effective against lung metastatic LL2 tumor in mouse model was established experimentally by an intravenous injection of tumors. Since regulatory T cells (Tregs) play an important role in immu

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!